

ANNOUNCEMENT



NZX / MEDIA RELEASE

28 August 2018

SeaDragon releases offer document in respect of its 1 for 1 rights offer

Rights offer document released

SeaDragon (NZX:SEA) today released its offer document for its 1 for 1 pro-rata renounceable rights offer, which opens today (28 August 2018).

The rights offer involves a pro-rata offer to all eligible shareholders of the right to acquire one new share for every one existing share held as of 5:00pm on the rights offer record date, being 29 August 2018, together with a shortfall bookbuild. The rights will be issued at no charge and will trade under code SEARC on the NZX Main Board. The price for exercising the rights will be \$0.0033 per right and new shares will be issued on the same terms as the existing ordinary shares.

The market will be notified with details of the lead manager for the shortfall bookbuild once that lead manager has been appointed.

Full details and terms of the offer are contained in the attached offer document.

Eligible shareholders will be sent a copy of the offer document together with a letter of entitlement and acceptance on 30 August 2018.

Eligible shareholders should note that the offer closes at 5:00pm on 28 September 2018.

For further information contact:

Colin Groves
Chairman
Tel: +64 21 928 003

About SeaDragon: www.seadragon.co.nz

SeaDragon Limited (NZX:SEA) is New Zealand's largest refiner and blender of high-quality, internationally certified concentrated fish oils and fractions, including Omega-3 oils. Our oils are sourced from fish caught in the clean and pure waters around New Zealand, in the Southern Ocean, and elsewhere. We have more than 20 years' experience processing fish oils and we are recognised for the quality and purity of our products. We supply health supplement manufacturers around the world to meet the burgeoning demand for pure, high-quality fish oils, which are scientifically proven to deliver significant human health benefits such as lowering the risk of heart disease, improving brain function and joint health. The majority of our supply is exported.